Christopher D. Alafi, Director, 10% Owner at Intra-Cellular Therapies, Inc. (ITCI), bought 130,000 shares at $16.33 ($2.1M) on 2016-12-06, disclosed to the SEC on 2016-12-07.
Open-market purchase of $2.1M ITCI by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.33 | 44,174 | $721K | 34.1% |
| 2 | $16.33 | 44,174 | $721K | 34.1% |
| 3 | $16.14 | 20,826 | $336K | 15.9% |
| 4 | $16.14 | 20,826 | $336K | 15.9% |
| Total | $16.27 avg | 130,000 | $2.1M | 100% |
| Filing → |
| ITCI | BUY | 2020-09-14 | $1.5M | — | Filing → |
| ITCI | BUY | 2020-09-11 | $590K | — | Filing → |
| ITCI | BUY | 2019-09-11 | $9.8M | — | Filing → |